Insights

Here’s why the Little Green Pharma (ASX:LGP) share price is down 5%

Following the TGA’s clarification of distribution requirements, the Australian medicinal cannabis producer faces a change of rules.
The post Here’s why the Little Green Pharma (ASX:LGP) share price is down 5% appeared first on The Motley Fool Australia. –

Shares in Little Green Pharma Ltd (ASX: LGP) are falling amid news the company’s distribution responsibilities have changed. At the time of writing, the Little Green Pharma share price is 64.5 cents – 5.84% less than its previous closing price.

Today, the medicinal cannabis producer announced it has revised its distribution agreements following Therapeutic Goods Administration (TGA) clarification.

The company also updated the market on an ongoing purchase order of its products by German wholesaler DEMECAN.

Let’s take a closer look at the latest news from Little Green Pharma.

Revised distribution agreements

According to Little Green Pharma, its revised agreements will see its distribution partners acting as distributors rather than wholesalers.

Under the agreements, distributors will still dispense Little Green Pharma’s products but the company will hold ownership until they’re sold to pharmacies.

The revisions follow the TGA’s issuance of notices to all medicinal cannabis wholesalers.

The notices clarified rules for the wholesaling of unregistered pharmaceutical products. Medicinal cannabis products are considered unregistered pharmaceuticals.

Little Green Pharma will soon receive revenue for sales to pharmacies, rather than to wholesalers.

However, the company said the changes will impact its revenue for the fourth quarter of 2021.

This will be due to distributors drawing from current stocks before new supply rates take effect.

The company’s revenue will increase when it sells products directly to pharmacies. However, its distribution costs will increase at the same time.

As a result, Little Green Pharma believes, beyond 2021, its profits will not be affected by the change.

However, the change will see the timing of the company’s cash receipts slightly impacted.

DEMECAN’s latest order

Recently, DEMECAN placed a $2.5 million purchase order for Little Green Pharma’s products.

Today, Little Green Pharma stated it’s still waiting on regulatory approvals required to import most of the order to Germany.

According to Little Green Pharma, roughly 7,000 units of its 9,000 unit order are awaiting routine approvals.

The company says there are no reasons DEMECAN won’t meet the approvals.

However, if it doesn’t, Little Green Pharma will package the halted products to be sold in Australia.

Little Green Pharma share price snapshot

Despite today’s fall, the Little Green Pharma share price has been performing well on the ASX lately.

Currently, it’s 14% higher than it was at the start of 2021. It’s also gained 69% since this time last year.

The company has a market capitalisation of around $90 million, with approximately 187 million shares outstanding.

The post Here’s why the Little Green Pharma (ASX:LGP) share price is down 5% appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

These are the 10 most shorted shares on the ASX

Top brokers just upgraded these ASX shares to “buy”

What’s lifting the Cash Converters (ASX:CCV) share price today?
Leading brokers name 3 ASX shares to sell today

Why the MoneyMe (ASX:MME) share price is rocketing 17% today

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. 

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!